• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

chronic lymphocytic leukemia

Job cuts employee layoffs firings or downsizing Scissors dividing individuals positioned on colorful blocks
Biotech

Nurix trims staff as trial for lead BTK degrader kicks off

The company declined to disclose how many employees were affected by the workforce reduction but added that no programs have been cut or paused.
Darren Incorvaia Nov 21, 2025 5:05am
BreyanziProductImageforMCL

Allogene abandons leukemia CAR-T plans after Breyanzi approval

Nov 14, 2024 5:59am
layoffs cuts restructuring

Tough markets take a double hit on Vincerx with layoffs

Jun 7, 2022 10:00am
Green traffic light

TG's leukemia combo clears phase 3, aims for 2020 filing

May 5, 2020 9:55am
Merck

Merck inks $2.7B ArQule deal, teeing up cancer race with Lilly

Dec 9, 2019 10:25am
Lilly

Lilly plots 'ambitious' cancer program after sharing early data

Dec 8, 2019 4:30pm

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2025 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings